Puig Montserrat, Mihalik Kathleen, Tilton John C, Williams Ollie, Merchlinsky Michael, Connors Mark, Feinstone Stephen M, Major Marian E
Laboratory of Hepatitis Viruses, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Hepatology. 2006 Sep;44(3):736-45. doi: 10.1002/hep.21319.
Hepatitis C is a major cause of chronic liver disease, with 170 million individuals infected worldwide and no available vaccine. We analyzed the effects of an induced T-cell response in 3 chimpanzees, targeting nonstructural proteins in the absence of neutralizing antibodies. In all animals the specific T-cell response modified the outcome of infection, producing a 10- to 1,000-fold reduction in peak virus titers. The challenge of 2 immunized animals that had been previously exposed to hepatitis C virus resulted in subclinical infections. Immune responses in the third animal, naive prior to immunization, limited viral replication immediately, evidenced by a 30-fold reduction in virus titer by week 2, declining to a nonquantifiable level by week 6. After 10 weeks of immunological control, we observed a resurgence of virus, followed by progression to a persistent infection. Comparing virus evolution with T-cell recognition, we demonstrated that: (i) resurgence was concomitant with the emergence of new dominant viral populations bearing single amino acid changes in the NS3 and NS5A regions, (ii) these mutations resulted in a loss of CD4+ T-cell recognition, and (iii) subsequent to viral resurgence and immune escape a large fraction of NS3-specific T cells became impaired in their ability to secrete IFN-gamma and proliferate. In contrast, NS3-specific responses were sustained in the recovered/immunized animals presenting with subclinical infections. In conclusion, viral escape from CD4+ T cells can result in the eventual failure of an induced T-cell response that initially controls infection. Vaccines that can induce strong T-cell responses prior to challenge will not necessarily prevent persistent HCV infection.
丙型肝炎是慢性肝病的主要病因,全球有1.7亿人感染,且尚无可用疫苗。我们分析了在3只黑猩猩中诱导T细胞反应的效果,该反应针对非结构蛋白且不存在中和抗体。在所有动物中,特异性T细胞反应改变了感染结果,使病毒峰值滴度降低了10至1000倍。对2只先前接触过丙型肝炎病毒的免疫动物进行攻击,导致亚临床感染。第三只动物在免疫前未接触过病毒,其免疫反应立即限制了病毒复制,第2周时病毒滴度降低了30倍,到第6周降至不可量化水平。在免疫控制10周后,我们观察到病毒复发,随后发展为持续性感染。将病毒进化与T细胞识别进行比较,我们发现:(i)复发与NS3和NS5A区域出现带有单个氨基酸变化的新优势病毒群体同时发生;(ii)这些突变导致CD4+T细胞识别丧失;(iii)病毒复发和免疫逃逸后,很大一部分NS3特异性T细胞分泌IFN-γ和增殖的能力受损。相比之下,在出现亚临床感染的恢复/免疫动物中,NS3特异性反应得以持续。总之,CD4+T细胞的病毒逃逸可导致最初控制感染的诱导T细胞反应最终失败。在受到攻击之前能够诱导强烈T细胞反应的疫苗不一定能预防持续性丙型肝炎病毒感染。